Avance Biosciences is offering a nextgen sequencing based assay for screening MGMT promoter methylation status. This assay is performed in compliance with GLP and GMP guideline on Illumina’s MiSeq platform. Avance Biosciences developed this assay to support a large scale brain cancer clinical trial where our nextgen based assay was used to validate a companion test based on real-time MSP technology.
Compared to other available methylation assays, our Next-Gen Sequencing based assay has the following advantages:
Low limit of quantitation
Able to probe many CpG positions
Able to report methylation at allele level